The purpose of this study was to evaluate the prognostic significance of the molecular detection of cytokeratin 19 (CK-19) mRNA-positive cells in the peripheral blood of women with operable breast cancer after the completion of adjuvant chemotherapy.
Introduction
Most patients with stage I or II breast cancer will be cured of their disease with surgery and adjuvant chemotherapy and hormone therapy; however, a significant proportion of patients with operable breast cancer may develop distant metastases.
The development of metastases is due to the migration of tumor cells from the original tumor to distant organs. This phenomenon probably occurs early during the evolution of the disease and even before the surgical excision of the primary tumor. In the last few years, several studies using either monoclonal antibodies against molecules expressed on epithelial cells, but not on mesenchymal cells, or molecular biology techniques permitted the detection of occult tumor cells in the bone marrow of patients with operable early stage I and II breast cancer [1] [2] [3] [4] [5] [6] [7] . Prospective studies have shown that the detection of occult tumor cells in the bone marrow aspirates of these patients is an independent adverse prognostic factor associated with decreased disease-free interval (DFI) and overall survival [2, [8] [9] [10] [11] [12] .
Bone marrow occult tumor cells have been shown to present several aberrations in chromosomes 7, 8 and 18, as well as amplification of the c-erbB2 gene, as detected by fluorescence in situ hybridisation [13, 14] . These findings strongly suggest that the occult epithelial bone marrow cells are most likely malignant in origin and may give rise to distant metastases. However, cell culture experiments have shown that these bone marrow occult tumor at Pennsylvania State University on February 23, 2013 http://annonc.oxfordjournals.org/ Downloaded from cells have a time-limited proliferative potential and thus may be dormant [15, 16] . The dormant status of the occult tumor cells may be the reason why adjuvant chemotherapy fails to prevent relapse in some patients with early breast cancer. Indeed, Braun et al. [17] used an immunohistochemical method to study 23 patients with inflammatory and 36 with operable breast cancer who had more than four involved axillary lymph nodes for the presence of occult bone marrow breast cancer cells before and after the completion of adjuvant chemotherapy; they found that 48.3% of patients who had cytokeratin (CK)-positive cells in the bone marrow before treatment became CK-negative post-treatment; multivariate analysis showed that the detection of CK-positive cells post-chemotherapy represents an independent poor prognostic factor for reduced overall survival [17] .
The above observations indicate that the detection of disseminated occult tumor cells may be an important marker to follow in patients with early breast cancer, because it may identify a subgroup of patients who are at high risk of relapse. Since multiple bone marrow aspirations from the same patient during the followup time can not be easily tolerated, the peripheral blood would be a more convenient source of sampling for such longitudinal follow-up studies. Indeed, occult tumor cells have already been identified by nested reverse-transcription polymerase chain reaction (RT-PCR) in the peripheral blood [4, 5, 7, [18] [19] [20] . Our group has recently evaluated the presence of circulating tumor cells expressing CK-19 mRNA by RT-PCR in the peripheral blood of patients with stage I and II breast cancer before the initiation of any adjuvant cytotoxic or hormone therapy; circulating CK-19 mRNA-positive cells could be detected in almost 30% of patients and multivariate analyses demonstrated that the presence of these cells was an independent prognostic factor for decreased DFI (P = 0.0007) and overall survival (P = 0.01) [21] .
In the present study we investigated the effect of the detection of CK-19 mRNA-positive cells in the peripheral blood after the completion of adjuvant chemotherapy on the risk of relapse, DFI and overall survival of patients with stage I and II breast cancer. Our data demonstrate that the presence of CK-19 mRNA-positive cells in the blood after the completion of adjuvant chemotherapy is an independent prognostic factor associated with increased risk of relapse and decreased DFI for patients with three or less involved axillary lymph nodes. Therefore, the detection of CK-19 mRNA-positive cells in the peripheral blood may be of clinical relevance during the follow-up of patients with operable breast cancer.
Patients and methods

Patients and clinical samples
Peripheral blood (10 ml in EDTA) was obtained from 161 patients with stage I and II breast cancer 4-8 weeks after the completion of adjuvant chemotherapy. The type of chemotherapy used in 87 patients was decided by the treating physician and included either the cyclophosphamide, methotrexate and 5-fluorouracil (CMF) or epirubicin, cyclophosphamide and 5-fluorouracil (FEC) regimen. In 59 patients with four or more positive axillary lymph nodes, adjuvant chemotherapy was based on a randomized study comparing four cycles of docetaxel 100 mg/m 2 In all cases peripheral blood samples were obtained at the middle of vein puncture after the first 5 ml of blood were discarded. Peripheral blood was diluted with an equal volume of phosphate-buffered saline (PBS; Gibco, UK) pH 7.3 and cells were dissociated by passing them through 25 guage 5/8 inch needles. Peripheral blood mononuclear cells (PBMC) were obtained by gradient density centrifugation using Ficoll-Hypaque 1077 (Sigma, USA) at 1200 g for 30 min at 4°C. The interface cells were removed, washed twice with 50 ml sterile PBS (pH 7.3), pelleted and resuspended in 1 ml PBS. The cells were pelleted again at 1200 g for 2 min. Cell pellets were kept at -80°C until RNA extraction. Total RNA isolation was performed by using Trizol LS reagent (Gibco, BRL) according to the manufacturer's instructions. All preparation and handling steps of RNA took place in a laminar flow hood under RNAse-free conditions. The isolated RNA was dissolved in diethylpyrocarbonate (DEPC)-treated water and stored at -80°C until use. RNA concentration was determined by absorbance readings at 260 nm with the Hitachi UV-VIS (U-2000)
spectrophotometer. RNA integrity was tested by PCR amplification of the β-actin housekeeping gene. RNA samples were also prepared from the human tumor cell lines MCF-7 and ARH-77 as positive and negative controls, respectively.
RT-PCR
Reverse transcription of RNA was carried out with the Thermoscript RT-PCR system (Gibco, BRL). c-DNA was synthesized according to the manufacturer's instructions. Two different PCR reactions, with the respective negative controls, were performed with each sample in order to amplify fragments of CK-19 and β-actin. The sequences of primers utilized (synthesized by Genset, Paris, France) were as follows: for CK-19, AAGCTAACCATGCA-GAACCTCAACGACCGC (forward; P1); TTATTGGAGGTCAGGAGAA-GAGCC (reverse; P2); TCCCGCGACTACAGCCACTACTACACGACC (forward; P3); CGCGACTTGATGTCCATGAGCCGCTGGTAC (reverse; P4); and for β-actin, CATCCTGTCGGCAATGCCAGG (forward; A1); CTTCTTGGGCATGGAGTCCTG (reverse; A2). The corresponding sizes of the PCR products were 745 and 154 base pairs, respectively. These primers extend across at least one intron; thus, the eventual DNA contamination would not pose a significant problem. CK-19 gene expression was evaluated by nested PCR as described by Datta et al. [4] . The conditions for β-actin PCR were one cycle at 94°C for 2 min, followed by 35 cycles at 94°C for 30 s, 60°C for 30 s, and 72°C for 45 s and a final extension at 72°C for 4 min. Ten microliters of all PCR products were electrophoresed on 2% agarose gels and visualized with ethidium bromide.
Statistical analysis
The main methods of analysis were logistic regression [22, 23] and the Cox proportional hazards model [24] for outcomes related to point events and time variables, respectively. To select those factors with independent significant influence on outcomes, both analyses were carried out in a stepwise (unconditional backward) fashion [23, 24] . Prior to the application of these methods, univariate analyses were performed for a preliminary exploration of marked associations. Univariate analyses included contingency tables (Pearson's χ 2 -test and its partition to components, or Fisher's test where appropriate, relative risks and/or odds ratios) and Kaplan-Meier estimates of survival curves (logrank and Wilcoxon tests) [24] [25] [26] .
Results
Detection of peripheral blood CK-19 mRNA-positive cells after the completion of adjuvant chemotherapy
Forty-four (27.3%) of 161 patients with operable breast cancer had detectable CK-19 mRNA-positive cells in peripheral blood after the completion of adjuvant chemotherapy. mRNA-positive cells in peripheral blood after the completion of adjuvant chemotherapy developed distant relapse during the follow-up period compared with 11 (9.4%) of 117 patients who had no such cells (P = 0.711). Moreover, none of the known clinicopathological prognostic factors showed any significant association with relapse; the only marked, but not significant (P = 0.086), association with relapse was the number of involved axillary nodes (if greater than three).
DFI. Kaplan-Meier estimates of the cumulative DFI rates showed no significant difference between patients with detectable CK-19 mRNA-positive cells in the peripheral blood after the completion of adjuvant chemotherapy and those patients with no such cells (P = 0.664). After a median follow-up of 29 months (range 7-55), the median times to tumor progression have not yet been attained in either group. The proportional hazards model revealed that age, menopausal status, tumor size, stage, histological grade and the presence of ER or PR did not have any influence on DFI, irrespective of the detection of CK-19 mRNA-positive cells in the peripheral blood after the completion of adjuvant chemotherapy. Only the number of involved axillary lymph nodes had a significant effect on DFI (P = 0.018); the hazard of relapse for patients with more than three involved lymph nodes was 4.2 times (95% CI 1.27-13.56) higher than that of patients with three or less involved lymph nodes. Moreover, the presence of CK-19 mRNA-positive cells in the peripheral blood after the completion of adjuvant chemotherapy had a significant effect on DFI, which was dependent upon the number of involved lymph nodes. More specifically, the hazard of relapse for patients with three or less involved lymph nodes and detectable CK-19 mRNA-positive cells after adjuvant chemotherapy was 3.81 (95% CI 1.06-13.71) times higher than that of patients with CK-19 mRNA-negative cells. In contrast, for patients with more than three involved lymph nodes, the presence of CK-19 mRNA-positive cells post-adjuvant chemotherapy did not affect significantly the risk of relapse (P = 0.509).
The above results were further illustrated by Kaplan-Meier analysis ( Figure 1A and B). Patients with three or less involved lymph nodes who had detectable CK-19 mRNA-positive cells in the peripheral blood after the completion of adjuvant chemotherapy had a significantly decreased DFI (log-rank test; P = 0.028) compared with that of patients without such cells in the peripheral blood ( Figure 1A) . However, for patients with more than three involved lymph nodes, the difference in the DFI rates according to the presence or absence of CK-19 mRNA-positive cells was not significant (log-rank test; P = 0.501; Figure 1B) .
Effect of type of adjuvant chemotherapy on DFI
The analysis by the proportional hazards model indicated significant interaction effects between types of regimen and presence of CK-19 mRNA-positive cells after the completion of adjuvant treatment. More specifically, for patients without detectable CK-19 mRNA-positive cells in the peripheral blood after the completion of adjuvant treatment, the type of chemotherapy regimen had no effect on DFI (Figure 2A ). In contrast, the type of regimen had a significant effect on the DFI of patients with detectable CK-19 mRNA-positive cells after adjuvant therapy. For these patients, the hazard of relapse associated with the CMF regimen was significantly higher (P = 0.022) than that of patients who were treated with either FEC or T/EC (hazards ratio 3.70; 95% CI 1.09-13.89) ( Figure 2B ). Patients treated with CMF had a worse DFI with a median of 38 months compared with the other two groups where the median DFIs have not yet been reached.
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Three ( 
Discussion
Although the prognostic significance of the detection of CKpositive cells in the bone marrow of patients with early breast cancer at initial diagnosis is well documented [2, 8, 10] , very few data exist on the prognostic value of the detection of such cells circulating in the peripheral blood. We have recently evaluated the detection of CK-19 mRNA-positive cells by RT-PCR in the peripheral blood of 148 patients with stage I and II breast cancer before the initiation of any adjuvant therapy and we found that the presence of such cells was an independent adverse prognostic factor associated with decreased DFI and overall survival [21] . In the present study we investigated the effect of the detection of CK-19 mRNA-positive cells in the peripheral blood after the completion of adjuvant chemotherapy in 161 patients with stage I and II breast cancer in association with the risk of relapse, DFI and overall survival. We found that in 27.3% of patients CK-19 mRNA-positive cells were detectable in the blood after the completion of adjuvant chemotherapy. This relative lack of efficacy of adjuvant chemotherapy to kill disseminated occult tumor cells has also been demonstrated by others [17] and may be due to the dormant nature of such cells [9, 15, 16] , thus reducing their sensitivity to chemotherapy. Alternative targeted therapies, such as monoclonal antibodies, that are able to eliminate resting cells may be more effective in eliminating disseminated occult tumor cells [27, 28] .
Overall there was no significant association of CK-19 mRNApositive cells in peripheral blood after the completion of adjuvant chemotherapy with the risk of distant relapse, DFI or overall survival. This is in contrast with the findings of Braun et al. [17] , where the presence of CK-positive cells in the bone marrow after adjuvant chemotherapy was an independent predictor for reduced overall survival (relative risk = 5.0; P = 0.016). However, there are significant differences between the two studies that may account for this discrepancy. In the study by Braun et al. [17] , only patients with inflammatory or advanced (greater than four nodes involved) disease who were at high risk of relapse were included. Furthermore, a different methodology was used (immunohistochemistry instead of RT-PCR) to detect occult tumor cells.
Interestingly, in subgroup analysis of the present study, the risk of relapse for patients with three or less involved axillary lymph nodes and detectable CK-19 mRNA-positive cells after adjuvant chemotherapy was almost four times higher and DFI was significantly decreased compared with that of patients without CK-19 mRNA-positive cells. There was no significant association between the presence of CK-19 mRNA-positive cells after adjuvant therapy and the risk of relapse in patients with more than three involved axillary lymph nodes. This difference in the prognostic value of CK-19 mRNA detection after adjuvant therapy in association with the number of involved axillary lymph nodes may be due to the different micrometastatic tumor load and the associated risk of relapse. It is well known that patients with more than three involved axillary lymph nodes have a higher risk of relapse compared with patients with three or less positive nodes [29] . Therefore, it is possible that the qualitative nested RT-PCR assay of CK-19 mRNA was able to discriminate the prognostic risk only in patients with a relatively low micrometastatic tumor load. Conversely, patients with a high micrometastatic tumor load, such as patients with more than three positive axillary lymph nodes, may require quantitative assessment of the micrometastatic disease for the accurate prediction of prognostic risk [19, 20] .
Another interesting finding of this study was the effect of the type of regimen used on DFI of patients with detectable CK-19 mRNA-positive cells in the peripheral blood after adjuvant treatment. The risk of relapse was significantly higher and DFI was reduced for patients receiving CMF as compared with either FEC or T/EC. Since all of these patients had circulating tumor cells following the completion of adjuvant therapy, the difference in the risk of relapse may be related to the different number of circulating tumor cells (tumor load) which may be affected by the type of adjuvant chemotherapy used. In order to demonstrate such an association, a quantitative assessment of circulating tumor cells is necessary using quantitative RT-PCR methodology [19, 20] .
The detection of minimal numbers of circulating breast cancer cells in the blood by RT-PCR of CK-19 mRNA has certain limitations, which have been well described [7] . False positive results may be due to the detection of CK-19 pseudogenes a and b [30] or even due to sample contamination with epithelial cells of skin during vein puncture [31] . Although the primers used in this study do not rule out amplification of these CK-19 pseudogenes, all blood samples were obtained at the middle of vein puncture in order to avoid blood contamination with epithelial cells. Moreover, because the RT-PCR assay detects minimal amounts of specific mRNA amongst a plethora of other RNA, the risk of illegitimate transcription of the CK-19 gene is increased. This may involve the ectopic transcription of the CK-19 gene in hematopoietic cells [32] or the expression of any gene in any cell type [33] . In a previous report [21] we have presented that by using this assay CK-19 mRNA-positive cells were detected in the blood of two of 54 (3.7%) healthy female blood donors and four of 28 (14.3%) patients with hematological malignancies. These findings may be explained by the aforementioned limitations of the assay. Furthermore, the administration of chemotherapy may adversely affect the sensitivity and specificity of the detection in many different ways. Chemotherapy could induce the secretion of pro-inflammatory cytokines, which could modify gene expression [34] . Cytotoxic agents may also cause mucositis and thus introduce normal epithelial cells into the circulation, which could be detected as CK-19 mRNA-positive cells. Alternatively, chemotherapy may induce apoptotic cancer cells in the blood, which could be detected by the molecular method.
In this study, we have demonstrated that the molecular detection of CK-19 mRNA-positive cells in the peripheral blood following adjuvant chemotherapy was an independent adverse prognostic factor for patients with three or less involved axillary lymph nodes, associated with increased risk of relapse and reduced DFI. Furthermore, for patients with CK-19 mRNA-positive cells in the blood after adjuvant therapy, the type of chemotherapy used had prognostic implications. Therefore, the detection of CK-19 mRNA-positive cells in the blood after the completion of adjuvant chemotherapy may be a useful surrogate test to assess the risk of relapse in patients with stage I and II breast cancer.
